Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors

NCT03283202 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

35

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse B-Cell Lymphoma

Interventions

DRUG: Avadomide (CC-122)
DRUG: Rituximab
DRUG: Cyclophosphamide 750mg/m2 by IV infusion
DRUG: Vincristine
DRUG: Prednisone

Sponsor

Celgene